20207541

Source:http://linkedlifedata.com/resource/pubmed/id/20207541

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0205198, umls-concept:C0205531, umls-concept:C0226896, umls-concept:C0243192, umls-concept:C0442027, umls-concept:C0597357, umls-concept:C0935763, umls-concept:C1527178, umls-concept:C1527415, umls-concept:C1705938, umls-concept:C1880355
pubmed:issue	7
pubmed:dateCreated	2010-3-22
pubmed:abstractText	We report the design, synthesis and properties of spiroindane based compound 1, a potent, selective, orally bioavailable, non-peptide melanocortin subtype-4 receptor agonist. Compound 1 shows excellent erectogenic activity in the rodent models.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9107377
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Indans, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Melanocortin, Type 4, http://linkedlifedata.com/resource/pubmed/chemical/Spiro Compounds
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	1464-3405
pubmed:author	pubmed-author:BakshiRaman KRK, pubmed-author:BallRichard GRG, pubmed-author:CashenDoreen EDE, pubmed-author:ChenAiru SAS, pubmed-author:ChenHoward YHY, pubmed-author:DellureficioJames PJP, pubmed-author:DobbelaarPeter HPH, pubmed-author:FongTung MTM, pubmed-author:FranklinChristopher LCL, pubmed-author:GuoLiangqinL, pubmed-author:HeShuwenS, pubmed-author:HongQingmeiQ, pubmed-author:JianTianyingT, pubmed-author:LaiYingjieY, pubmed-author:LiuJianJ, pubmed-author:MacintyreD EuanDE, pubmed-author:MacneilTanyaT, pubmed-author:MartinWilliam JWJ, pubmed-author:MillerRandy RRR, pubmed-author:NargundRavi PRP, pubmed-author:PengQianpingQ, pubmed-author:SebhatIyassu KIK, pubmed-author:StearnsRalph ARA, pubmed-author:StrackAlison MAM, pubmed-author:TamvakopoulosConstantinC, pubmed-author:TangRuiR, pubmed-author:TsouNancy NNN, pubmed-author:WeinbergDavid HDH, pubmed-author:WyvrattMatthew JMJJr, pubmed-author:YeZhixiongZ
pubmed:copyrightInfo	2010 Elsevier Ltd. All rights reserved.
pubmed:issnType	Electronic
pubmed:day	1
pubmed:volume	20
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	2106-10
pubmed:meshHeading	pubmed-meshheading:20207541-Animals, pubmed-meshheading:20207541-CHO Cells, pubmed-meshheading:20207541-Cricetinae, pubmed-meshheading:20207541-Cricetulus, pubmed-meshheading:20207541-Dogs, pubmed-meshheading:20207541-Erectile Dysfunction, pubmed-meshheading:20207541-Haplorhini, pubmed-meshheading:20207541-Humans, pubmed-meshheading:20207541-Indans, pubmed-meshheading:20207541-Male, pubmed-meshheading:20207541-Mice, pubmed-meshheading:20207541-Molecular Structure, pubmed-meshheading:20207541-Protein Binding, pubmed-meshheading:20207541-Rats, pubmed-meshheading:20207541-Receptor, Melanocortin, Type 4, pubmed-meshheading:20207541-Spiro Compounds, pubmed-meshheading:20207541-Structure-Activity Relationship
pubmed:year	2010
pubmed:articleTitle	Discovery of a spiroindane based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor agonist.
pubmed:affiliation	Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065-0900, USA. shuwen_he@merck.com
pubmed:publicationType	Journal Article